Revelation Biosciences, Inc. (NASDAQ:REVBW – Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totaling 2,237 shares, a decrease of 63.0% from the September 30th total of 6,042 shares. Based on an average daily volume of 30,036 shares, the days-to-cover ratio is presently 0.1 days.
Revelation Biosciences Price Performance
Shares of Revelation Biosciences stock traded up $0.00 during midday trading on Friday, reaching $0.01. 23,247 shares of the company’s stock traded hands, compared to its average volume of 53,112. The stock has a 50 day moving average of $0.01 and a 200-day moving average of $0.01. Revelation Biosciences has a 12 month low of $0.00 and a 12 month high of $0.04.
About Revelation Biosciences
Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that harness the body’s innate immune system to prevent and treat disease. The company’s programs are based primarily on Gemini, its proprietary formulation of an innate immune modulator designed for administration through the nose.
Revelation’s product candidates are being investigated for potential use in respiratory and other infectious diseases, with research aimed at stimulating an early immune response in the nasal passages and airways.
Featured Articles
- Five stocks we like better than Revelation Biosciences
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
